Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism

Journal of Immunology

Volumn 166, Issue 11, 2001, Pages 6608-6615

  Peláez, Blondineth ^a   Campillo, José A ^a   López Asenjo, José A ^a   Subiza, José L ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; NITRIC OXIDE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DRUG MECHANISM; EHRLICH ASCITES TUMOR; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 17544401819     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.11.6608     Document Type: Article

References (64)

1. Subiza, J. L., L. Cifuentes, and M. T. Medina. 1995. Prospects in cancer vaccines. Cancer J. 8:293.
2. Greenberg, P. D. 1990. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281.
3. Gold, J. E., D. T. Zachary, and M. E. Osband. 1994. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma. Clin. Immunol. Immunopathol. 73:115.
4. Pockaj, B. A., R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carrasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang. 1994. Localization of 111 indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: augmentation with cyclophosphamide and correlation with response. Cancer 73:1731.
5. Berd, D., M. J. Mastrangelo, P. F. Engstrom, A. Paul, and H. Maguire. 1982. Augmentation of the human immune response by cyclophosphamide. Cancer Res. 42:4862.
6. North, R. J. 1982. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155:1063.
7. Proietti, E., G. Greco, B. Garrone, S. Baccarin, C. Mauri, M. Venditti, D. Carlei, and F. Belardelli. 1998. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. 101:429.
8. Schiavoni, G., F. Mattei, T. Santini, S. M. Bracci, L. F. Belardelli, and E. Proietti. 2000. Cylophosphamide induces type I interferon and augments the number of CD44 (hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95:2024.
9. + T-cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity. Blood 89:2529.
10. Segre, M., E. Tomei, and D. Segre. 1985. Cyclophosphamide-induced suppressor cells in mice: suppression of the antibody response in vitro and characterization of the effector cells. Cell. Immunol. 91:443.
11. Nikcevich, D. A., G. P. Duffie, R. Young, N. K. Ellis, G. E. Kaufman, and H. T. Wepsic. 1987. Stimulation of suppressor cells in the bone marrow and spleen of high dose cyclophosphamide-treated C57BL/6 mice. Cell. Immunol. 109:349.
12. Brooks-Kaise, J. C., L. A. Bourque, and D. W. Hoskin. 1991. Heterogeneity of splenic natural suppressor cells induced in mice by treatment with cyclophosphamide. Immunopharmacology 25:117.
13. Maier, T., J. H. Holda, K. L. Choi, and H. N. Claman. 1989. Characterization and function of the natural suppressor cells systems. In Functions of the Natural Immune System. C. W. Reynolds and R. H. Wiltrout, eds. Plenum Press, New York, p. 267.
14. Holda, J. H., T. Maier, and H. N. Claman. 1985. Murine graft-versus-host disease across minor barriers: immunosuppressive aspects of natural suppressor cells. Immunol. Rev. 88:87.
15. Strober, S. 1984. Natural suppressor (NS) cells, neonatal tolerance and total lymphoid irradiation: exploring obscure relationships. Annu. Rev. Immunol. 2:219.
16. Subiza, J. L., J. E. Viñuela, R. Rodríguez, J. Gil, M. A. Figueredo, and E. de la Concha. 1989. Development of splenic natural suppressor (NS) cells in Ehrlich tumor-bearing mice. Int. J. Cancer 44:307.
17. Sugiura, K., M. Inaba, H. Ogata, R. Yasumuzu, E. Sardiña, K. Inaba, S. Kuma, R. A. Good, and S. Ikehara. 1990. Inhibition of tumor cell proliferation by natural suppressor cells present in murine bone marrow. Cancer Res. 50:2582.
18. Seledtsov, V. I., V. Y. Taraban, G. V. Seledtsov, D. M. Samarin, I. V. Avdeev, V. V. Senyukov, and V. A. Kozlov. 1997. Tumor growth inhibitory and natural suppressor activities of murine bone marrow cells: a comparative study. Cell. Immunol. 182:12.
19. Maier, T., J. H. Holda, and H. N. Claman. 1986. Natural suppressor (NS) cells. Immunol. Today 7:312.
20. Holda, J. H., T. Maier, and H. N. Claman. 1988. Evidence that IFN-γ is responsible for natural suppressor activity in GVHD spleen and normal bone marrow. Transplantation 45:772.
21. Rodriguez, R., I. Angulo, J. E. Viñuela, M. Medina, J. Gil, and J. L. Subiza. 1994. Inhibition of bone marrow-derived natural suppressor activity by glucocorticoids and its reversal by IFN-γ or IL-2. Transplantation 58:511.
22. Angulo, I., R. Rodriguez, B. García, M. Medina, J. Navarro, and J. L. Subiza. 1995. Involvement of nitric oxide in bone marrow-derived natural suppressor activity. Its dependence of IFN-γ. J. Immunol. 155:15.
23. Angulo, I., J. Rullas, J. A. Campillo, E. Obregón, A. Heath, M. Howard, M. A. Muñoz-Fernández, and J. L. Subiza. 2000. Early myeloid cells are high producers of nitric oxide upon CD40 plus IFN-γ stimulation through a mechanism dependent on endogenous TNF-α and IL-1α. Eur. J. Immunol. 30:1263.
24. + cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 95:212.
25. Hibbs, J. B., Jr., R. R. Taintor, and Z. Vavrin. 1987. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 235:473.
26. Souza-Fiho, M. V., M. V. Lima, M. M. Pompeu, G. Ballejo, F. Q. Cunha, and R. A. Ribeiro. 1997. Involvement of nitric oxide in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis. Am. J. Pathol. 150:247.
27. Haddad, I. Y., A. Panoskaltsis-Mortari, D. H. Ingbar, S. Yang, C. E. Milla, and B. R. Blazar. 1999. High levels of peroxynitrite are generated in the lung of irradiated mice given cyclophosphamide and allogeneic T-cells: a potential mechanism of injury after marrow transplantation. Am. J. Respir. Cell. Mol. Biol. 20:1125.
28. Rothe, H., A. Faust, U. Schade, R. Klemann, G. Bosse, T. Hibino, S. Martin, and H. Kolb. 1994. Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-γ, but not of interleukin-4. Diabetologia 37:1154.
29. Leenen, P. J. M., M. Melis, W. A. T. Slieker, and W. Van Ewijk. 1990. Murine macrophage precursor characterization. II. Monoclonal antibodies against macrophage precursor antigens. Eur. J. Immunol. 20:27.
30. Heath, A. W., W. W. Wu, and M. C. Howard. 1994. Monoclonal antibodies to murine CD40 define two distinct functional epitopes. Eur. J. Immunol. 24:1828.
31. Liew, F. Y., S. Millott, C. Parkinson, R. M. J. Palmer, and S. Moncada. 1990. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J. Immunol. 144:4794.
32. Gil, J., J. Alvarez, J. E. Viñuela, J. G. Ruiz de Morales, A. Bustos, E. G. de la Concha, and J. L. Subiza. 1990. Inhibition of in vivo tumor growth by a monoclonal IgM antibody recognizing tumor cell-surface carbohydrates. Cancer Res. 50:7301.
33. Sheibani, K., and R. R. Tubbs. 1984. Enzyme immunohistochemistry: technical aspects. Semin. Diag. Pathol. 1:235.
34. + natural suppressor cells on IL-2 and IL-4 utilization in MLR. Transplantation 58:1096.
35. Chabner, B. A., C. J. Allegra, G. A. Curt, and P. Calabresi. 1996. Antineoplastic agents. In The Pharmacological Basis of Therapeutics, 9th Ed. Goodman & Gilman's, p. 1233.
36. Fisher, B., B. S. Packard, E. J. Read, J. A. Carrasquillo, C. S. Carter, S. L. Topalian, J. C. Yang, P. Yolles, S. M. Larson, and S. A. Rosenberg. 1989. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanomal. J. Clin. Oncol. 7:250.
37. Baggiolini, M., B. Dewald, and B. Moser. 1993. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv. Immunol. 55:97.
38. Broxmeyer, H. E., B. Sherry, L. Lu, S. Cooper, C. Carow, S. D. Wolpe, and A. Cerami. 1989. Myelopoietic enhancing effect of recombinant murine macrophage inflammatory protein 1 and 2 on colony formation in vitro by murine and human bone marrow granulocyte/macrophage progenitor cells. J. Exp. Med. 170: 1583.
39. Chen, L., and J. F. Watkins. 1970. Evidence against the presence of H-2 histocompatibility antigens in Ehrlich ascites tumor cells. Nature 225:734.
40. Marincola, F. M., E. M. Jaffee, D. J. Hicklin, and S. Ferrone. 2000. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74:181.
41. Neben, S., K. Marcus, and P. Mauch. 1993. Mobilization of hematopoietic stem and progenitor cells subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood 81:1960.
42. Morrison, S. J., D. E. Wright, and I. L. Weissman. 1997. Cyclophosphamide/ granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc. Natl. Acad. Sci. USA 94:1908.
43. Radi, R., J. S. Beckman, K. M. Bush, and B. A. Freeman. 1991. Peroxynitrite oxidation of sulphydryls: the cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem. 266:4244.
44. Awwad, M., and R. J. North. 1990. Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of establish tumors. Cancer Res. 50:2228.
45. Cameron, R. B., P. J. Spiess, and S. A. Rosenberg. 1990. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation: studies on the mechanism of action. J. Exp. Med. 171:249.
46. Weiss, L., I. Lubin, I. Factorowich, L. Zvi, S. Reich, Y. Reisner, and S. Slavin. 1994. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma: role of cell therapy and recombinant IL-2. J. Immunol. 153:2562.
47. Schaafsma, M. R., W. E. Fibbe, D. V. D. Harts, N. Duinkerken, A. Brand, S. Osanto, C. R. Franks, R. Willemze, and J. H. F. Falkenburg. 1990. Increased numbers of circulating hematopoietic progenitor cells after treatment with high-dose interleukin-2 in cancer patients. Br. J. Haematol. 76:180.
48. Reya, T., N. V. Contractor, M. S. Couzens, M. A. Wasik, S. G. Emerson, and S. R. Carding. 1998. Abnormal myelocytic cell development in interleukin-2 (IL-2)-deficient mice: evidence for the involvement of IL-2 in myelopoiesis. Blood 91:2935.
49. Holda, J. H., T. Maier, and H. N. Claman. 1986. Natural suppressor activity in graft-vs-host spleen and normal bone marrow is augmented by IL 2 and interferon-γ. J. Immunol. 137:3538.
50. Yim, C.-Y., J. R. McGregor, O.-D. Kwon, N. R. Bastian, M. Rees, M. Mori, J. B. Hibbs, Jr., and W. E. Samlowski. 1995. Nitric oxide synthesis contributes to IL-2-induced antitumor responses against intraperitoneal Meth A tumor. J. Immunol. 155:4382.
51. Pericle, F., R. A. Kirken, P. K. Epling-Brunette, D. K. Blanchard, and J. Y. Djeu. 1996. Direct killing of interleukin-2-transfected tumor cells by human neutrophils. Int. J. Cancer 3:367.
52. Ueno, Y., Y. Kohgo, S. Sakamaki, Y. Itoh, M. Takahashi, Y. Hirayama, and Y. Niitsu. 1994. Immunochemotherapy in B-16-melanoma-cell-transplanted mice with combinations of interleukin-2, cyclophosphamide and PSK. Oncology 51: 296.
53. Viñuela, J. E., R. Rodríguez, J. Gil, J. Coll, E. G. de la Concha, and J. L. Subiza. 1991. Antigen shedding vs. development of natural suppressor cells as mechanism of tumor escape in mice bearing Ehrlich tumor. Int. J. Cancer 47:86.
54. Young, M. R., M. A. Wright, J. P. Matthews, I. Malik, and M. Perchel. 1996. Suppression of T-cells proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-β and nitric oxide. J. Immunol. 156:1916.
55. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. 165:779.
56. Ruiz de Morales, J. M. G., D. Vélez, and J. L. Subiza. 1999. Ehrlich tumor stimulates extramedullar hematopoiesis in mice without secreting identifiable colony-stimulating factors and without engagement of host T cells. Exp. Hematol. 27:1757.
57. Kusmartsev, S., J. M. G. Ruiz de Morales, J. Rullas, G. Danilets, and J. L. Subiza. 1999. Sialoadhesin expression by bone marrow macrophages derived from Ehrlich-tumor-bearing mice. Cancer Immunol. Immunother. 48:493.
58. Young, M. R., M. A. Wright, Y. Lozano, J. P. Matthews, J. Benefield, and M. M. Perchel. 1996. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int. J. Cancer 67:333.
59. Ding, A., C. F. Nathan, J. Graycar, R. Derynck, D. J. Stuehr, and S. Srimal. 1990. Macrophage deactivating factor and transforming growth factor-β1, -β2 and -β3 inhibit induction of macrophage-nitrogen oxide synthesis by IFN-γ. J. Immunol. 145:940.
60. Vodovotz, Y., L. Chesler, H. Chong, S.-J. Kim, J. T. Simpson, W. Degraff, G. W. Cox, A. B. Roberts, D. A. Wink, and M. H. Barcellos-Hoff. 1999. Regulation of transforming growth factor B1 by nitric oxide. Cancer Res. 59:2142.
61. Gorelik, E. 1983. Concomitant tumor immunity and the resistance to a second tumor challenge. Adv. Cancer Res. 39:71.
62. Nomi, S., K. Naito, B. D. Kahan, and N. R. Pellis. 1986. Effects of concomitant and siecomitant immunity on postsurgical metastasis in mice. Cancer Res. 46: 6111.
63. Akporiaye, E., S. J. Stewart, A. P. Stevenson, and C. C. Stewart. 1985. A gelatin sponge model for studying tumor growth: flow cytometric analysis and quantitation of leukocytes and tumor cells in the EMT6 mouse tumor. Cancer Res. 45:6457.
64. Characiejus, D., H. F. Dullens, and O. W. Den. 1990. Mechanisms of rejection in the murine DBA/2-SL2 concomitant immunity system. Cancer Immunol. Immunother. 32:179.